- Project Solace is the largest medical psilocybin and data project to date
- The project is in collaboration between Canadian non-profit TheraPsil and the UK’s Drug Science
- The company is a designated supplier, providing cGMP psilocybin to Project Solace participants
- Project Solace aims to expand legal access to psilocybin medicine for Canadian patients suffering from conditions such as end-of-life distress, Major Depressive Disorder, and other serious conditions
- Havn Life Sciences Inc. (HAVN) is down 9.09 percent trading at C$0.05 as of 10:51 am EDT
Havn Life Sciences (HAVN) has announced its participation in Project Solace, launching in Canada this July.
The project is a collaboration between Canadian non-profit TheraPsil and the UK’s Drug Science. It will be the largest medical psilocybin and data project to date, providing a safe supply of psilocybin to patients in medical need.
Project Solace aims to expand legal access to psilocybin medicine for Canadian patients suffering from end-of-life distress, Major Depressive Disorder (MDP), and other severe conditions for which traditional treatment options have failed.
While doing this, the company says Project Solace “aims to develop a substantial body of evidence, using a real-world data (RWD) registry, to document clinical effectiveness, safety, and clinician and patient-reported outcomes in patients who have received psilocybin-assisted psychotherapy by access to psilocybin through Canada’s Special Access Program (SAP).”
Project Solace will begin assisting patients in five primary regions in B.C., Ontario, and Quebec, with plans to expand as additional treatment teams are onboarded.
Patients will be connected to prescribing healthcare professionals who can request cGMP psilocybin from designated suppliers enrolled in Project Solace, including HAVN Life, Filament Health, and Psygen.
Health Canada has designated the Special Access Program (SAP) and clinical trials as a preferred pathway for patients to access psilocybin for medical purposes. Under SAP, prescribing healthcare professionals can request psilocybin, manufactured by Health Canada-approved licensed dealers, for seriously-ill patients who require emergency access to this medicine.
HAVN Life Sciences’ CEO, Tim Moore commented on the news.
“We are honored to participate in Project Solace, the first-of-its-kind that will provide thousands of Canadians with a life-changing opportunity to receive psilocybin-assisted therapy,” says “Projects like these speak to the very foundation of HAVN Life, which is to support and serve communities in need of cognitive and mental health treatment alternatives and help them achieve their full potential. We are excited to be part of this potentially transformative effort on the path towards full Health Canada approval.”
The anonymized data collected through Project Solace will be provided to regulatory bodies, including Health Canada, to facilitate decision-making surrounding the regulatory system for the future of medicalized psilocybin.
Data collected from Project Solace will be a critical tool for prescribing healthcare professionals and help future patients decide which licensed producers of psilocybin products best suit their medical needs.
The data will also be released to designated suppliers enrolled in the RWD program and the general public.
Havn Life Sciences is a biotechnology co. pursuing standardized extraction of psychoactive compounds and the development of natural health products.
The company’s operations, located in Jamaica, are facilitated by strategic partnerships with Hypha Wellness and P.A. Benjamin Manufacturing Company to provide cultivation and processing facilities for psilocybin containing mushrooms, solidifying relationships with local partners.
Havn Life Sciences Inc. (HAVN) is down 9.09 percent trading at C$0.05 as of 10:51 am EDT.